NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1033 coverCarnitine: The Science behind a Conditionally Essential Nutrient Volume 1033 published November 2004
Ann. N.Y. Acad. Sci. 1033: 158–167 (2004). doi: 10.1196/annals.1320.015
Copyright © 2004 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via Google Scholar
Google Scholar
Articles by BENVENGA, S.
Articles by TRIMARCHI, F.
Search for Related Content
PubMed
PubMed Citation
Articles by BENVENGA, S.
Articles by TRIMARCHI, F.
Effects of Carnitine on Thyroid Hormone Action

SALVATORE BENVENGAa,b, ANTONINO AMATOc, MENOTTI CALVANId AND FRANCESCO TRIMARCHIa

aSezione di Endocrinologia, Dipartimento Clinico Sperimentale di Medicina e Farmacologia, University of Messina School of Medicine, 98125 Messina, Italy
bProgramma Infradipartimentale di Endocrinologia Molecolare Clinica, Azienda Ospedaliera Universitaria Policlinico Gaetano Martino, 98125 Messina, Italy
cSigma-Tau Research, Incorporated, Gaithersburg, Maryland 20877, USA
dSigma-Tau S.p.A., 00040 Pomezia, Roma, Italy

Address for correspondence: Prof. Salvatore Benvenga, Sezione di Endocrinologia, Dipartimento Clinico Sperimentale di Medicina e Farmacologia, University of Messina School of Medicine, and Programma Infradipartimentale di Endocrinologia Molecolare Clinica, Azienda Ospedaliera Universitaria Policlinico Gaetano Martino, 98125 Messina, Italy. Voice: +39-090-221-3840; fax: +39-090-221-3518. s.benvenga{at}me.nettuno.it; sbenvenga{at}unime.it

By experiments on cells (neurons, hepatocytes, and fibroblasts) that are targets for thyroid hormones and a randomized clinical trial on iatrogenic hyperthyroidism, we validated the concept that l-carnitine is a peripheral antagonist of thyroid hormone action. In particular, l-carnitine inhibits both triiodothyronine (T3) and thyroxine (T4) entry into the cell nuclei. This is relevant because thyroid hormone action is mainly mediated by specific nuclear receptors. In the randomized trial, we showed that 2 and 4 grams per day of oral l-carnitine are capable of reversing hyperthyroid symptoms (and biochemical changes in the hyperthyroid direction) as well as preventing (or minimizing) the appearance of hyperthyroid symptoms (or biochemical changes in the hyperthyroid direction). It is noteworthy that some biochemical parameters (thyrotropin and urine hydroxyproline) were refractory to the l-carnitine inhibition of thyroid hormone action, while osteocalcin changed in the hyperthyroid direction, but with a beneficial end result on bone. A very recent clinical observation proved the usefulness of l-carnitine in the most serious form of hyperthyroidism: thyroid storm. Since hyperthyroidism impoverishes the tissue deposits of carnitine, there is a rationale for using l-carnitine at least in certain clinical settings.

Key Words: carnitine • thyroid hormone • T3 • T4 • hyperthyroid • bone mineral density (BMD)






footerLeft footerRight